25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

RespireRx Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyze Respirerx together

I guess you are interested in RespireRx Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of RespireRx Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about RespireRx Pharmaceuticals Inc

I send you an email if I find something interesting about RespireRx Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Respirerx (30 sec.)










1.2. What can you expect buying and holding a share of Respirerx? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.03
Expected worth in 1 year
$-0.04
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
$-0.02
Return On Investment
-2,268.3%

For what price can you sell your share?

Current Price per Share
$0.00
Expected price per share
$0.0004 - $0.0008
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Respirerx (5 min.)




Live pricePrice per Share (EOD)
$0.00
Intrinsic Value Per Share
$0.00 - $0.01
Total Value Per Share
$-0.03 - $-0.02

2.2. Growth of Respirerx (5 min.)




Is Respirerx growing?

Current yearPrevious yearGrowGrow %
How rich?-$11.8m-$10m-$1.8m-15.8%

How much money is Respirerx making?

Current yearPrevious yearGrowGrow %
Making money-$2m-$3.8m$1.8m91.4%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Respirerx (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Respirerx?

Welcome investor! Respirerx's management wants to use your money to grow the business. In return you get a share of Respirerx.

First you should know what it really means to hold a share of Respirerx. And how you can make/lose money.

Speculation

The Price per Share of Respirerx is $0.0007. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Respirerx.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Respirerx, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.03. Based on the TTM, the Book Value Change Per Share is $0.00 per quarter. Based on the YOY, the Book Value Change Per Share is $0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Respirerx.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.01-1,203.1%-0.01-1,203.1%-0.01-1,066.8%-0.01-1,086.8%-0.01-1,556.7%
Usd Book Value Change Per Share0.00-567.1%0.00-567.1%0.00-588.8%0.00-455.8%0.00-269.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.00-567.1%0.00-567.1%0.00-588.8%0.00-455.8%0.00-269.2%
Usd Price Per Share0.00-0.00-0.01-0.15-0.48-
Price to Earnings Ratio-0.27--0.27--1.57--28.54--42.45-
Price-to-Total Gains Ratio-0.58--0.58--2.84--51.15--20.99-
Price to Book Ratio-0.09--0.09--0.55--12.13--43.77-
Price-to-Total Gains Ratio-0.58--0.58--2.84--51.15--20.99-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0007
Number of shares1428571
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (1428571 shares)-5,670.67-4,557.55
Gains per Year (1428571 shares)-22,682.68-18,230.18
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-22683-226930-18230-18240
20-45365-453760-36460-36470
30-68048-680590-54691-54700
40-90731-907420-72921-72930
50-113413-1134250-91151-91160
60-136096-1361080-109381-109390
70-158779-1587910-127611-127620
80-181461-1814740-145841-145850
90-204144-2041570-164072-164080
100-226827-2268400-182302-182310

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%1.033.01.02.9%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%3.07.00.030.0%12.021.02.034.3%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%4.00.031.011.4%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%3.07.00.030.0%13.021.01.037.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of RespireRx Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.004-0.0040%-0.004+4%-0.003-20%-0.002-53%
Book Value Per Share---0.025-0.0250%-0.021-16%-0.018-27%-0.013-47%
Current Ratio--0.0020.0020%0.021-91%0.012-84%0.023-91%
Debt To Asset Ratio--522.501522.5010%48.944+968%175.924+197%104.569+400%
Debt To Equity Ratio----0%-0%-0%-0%
Dividend Per Share----0%-0%-0%-0%
Eps---0.008-0.0080%-0.007-11%-0.008-10%-0.011+29%
Free Cash Flow Per Share--0.0000.0000%-0.002+564%-0.001+251%-0.002+450%
Free Cash Flow To Equity Per Share--0.0000.0000%0.000-328%0.000+1200%0.000+13749%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--0.008--------
Intrinsic Value_10Y_min---0.004--------
Intrinsic Value_1Y_max---0.001--------
Intrinsic Value_1Y_min---0.001--------
Intrinsic Value_3Y_max---0.001--------
Intrinsic Value_3Y_min---0.003--------
Intrinsic Value_5Y_max--0.000--------
Intrinsic Value_5Y_min---0.004--------
Market Cap330218.694-229%1085004.2821085004.2820%5519369.606-80%72355633.353-99%226280001.633-100%
Net Profit Margin----0%-0%-0%-22.5340%
Operating Margin----0%-0%-0%-11.6690%
Operating Ratio----0%-0%-0%11.873-100%
Pb Ratio-0.028+70%-0.091-0.0910%-0.552+504%-12.126+13178%-43.767+47823%
Pe Ratio-0.083+70%-0.273-0.2730%-1.567+474%-28.538+10350%-42.448+15443%
Price Per Share0.001-229%0.0020.0020%0.012-80%0.153-99%0.480-100%
Price To Free Cash Flow Ratio-2.295+70%-7.540-7.5400%-5.772-23%-166.037+2102%-267.533+3448%
Price To Total Gains Ratio-0.176+70%-0.579-0.5790%-2.839+390%-51.146+8727%-20.992+3523%
Quick Ratio--0.0000.0000%0.000-95%0.002-100%0.012-100%
Return On Assets---88.770-88.7700%-18.538-79%-48.146-46%-40.432-54%
Return On Equity----0%-0%-0%-0%
Total Gains Per Share---0.004-0.0040%-0.004+4%-0.003-20%-0.002-53%
Usd Book Value---11880320.000-11880320.0000%-10007758.000-16%-8625894.400-27%-6302013.700-47%
Usd Book Value Change Per Share---0.004-0.0040%-0.004+4%-0.003-20%-0.002-53%
Usd Book Value Per Share---0.025-0.0250%-0.021-16%-0.018-27%-0.013-47%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.008-0.0080%-0.007-11%-0.008-10%-0.011+29%
Usd Free Cash Flow---143900.000-143900.0000%-956172.000+564%-505637.200+251%-792047.400+450%
Usd Free Cash Flow Per Share--0.0000.0000%-0.002+564%-0.001+251%-0.002+450%
Usd Free Cash Flow To Equity Per Share--0.0000.0000%0.000-328%0.000+1200%0.000+13749%
Usd Market Cap330218.694-229%1085004.2821085004.2820%5519369.606-80%72355633.353-99%226280001.633-100%
Usd Price Per Share0.001-229%0.0020.0020%0.012-80%0.153-99%0.480-100%
Usd Profit---2022267.000-2022267.0000%-3869609.000+91%-3170049.200+57%-4410708.200+118%
Usd Revenue----0%-0%-0%13522.500-100%
Usd Total Gains Per Share---0.004-0.0040%-0.004+4%-0.003-20%-0.002-53%
 EOD+2 -6MRQTTM+0 -0YOY+11 -165Y+8 -1910Y+11 -18

3.3 Fundamental Score

Let's check the fundamental score of RespireRx Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.083
Price to Book Ratio (EOD)Between0-1-0.028
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than10.002
Debt to Asset Ratio (MRQ)Less than1522.501
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-88.770
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of RespireRx Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.536
Ma 20Greater thanMa 500.001
Ma 50Greater thanMa 1000.001
Ma 100Greater thanMa 2000.001
OpenGreater thanClose0.001
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About RespireRx Pharmaceuticals Inc

RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. It has a research collaboration with University College London to the use of AMPAkines for the treatment of GRIA disorders. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.

Fundamental data was last updated by Penke on 2024-11-14 02:40:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Respirerx earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Respirerx to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of RespireRx Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-2,253.4%+2,253.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--115.9%+115.9%
TTM--210.8%+210.8%
YOY--214.5%+214.5%
5Y--342.2%+342.2%
10Y-2,253.4%-464.5%-1,788.9%
4.3.1.2. Return on Assets

Shows how efficient Respirerx is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Respirerx to the Biotechnology industry mean.
  • -8,877.0% Return on Assets means that Respirerx generated $-88.77 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of RespireRx Pharmaceuticals Inc:

  • The MRQ is -8,877.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -8,877.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8,877.0%TTM-8,877.0%0.0%
TTM-8,877.0%YOY-1,853.8%-7,023.2%
TTM-8,877.0%5Y-4,814.6%-4,062.4%
5Y-4,814.6%10Y-4,043.2%-771.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8,877.0%-11.1%-8,865.9%
TTM-8,877.0%-11.7%-8,865.3%
YOY-1,853.8%-11.3%-1,842.5%
5Y-4,814.6%-12.7%-4,801.9%
10Y-4,043.2%-14.3%-4,028.9%
4.3.1.3. Return on Equity

Shows how efficient Respirerx is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Respirerx to the Biotechnology industry mean.
  • 0.0% Return on Equity means Respirerx generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of RespireRx Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--14.2%+14.2%
TTM--15.8%+15.8%
YOY--13.9%+13.9%
5Y--18.5%+18.5%
10Y--19.5%+19.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of RespireRx Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Respirerx is operating .

  • Measures how much profit Respirerx makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Respirerx to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of RespireRx Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-1,166.9%+1,166.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--258.6%+258.6%
TTM--318.3%+318.3%
YOY--224.0%+224.0%
5Y--386.5%+386.5%
10Y-1,166.9%-497.6%-669.3%
4.3.2.2. Operating Ratio

Measures how efficient Respirerx is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of RespireRx Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y11.873-11.873
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.594-2.594
TTM-3.360-3.360
YOY-3.299-3.299
5Y-4.788-4.788
10Y11.8736.528+5.345
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of RespireRx Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Respirerx is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.00 means the company has $0.00 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of RespireRx Pharmaceuticals Inc:

  • The MRQ is 0.002. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.002. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.002TTM0.0020.000
TTM0.002YOY0.021-0.019
TTM0.0025Y0.012-0.010
5Y0.01210Y0.023-0.011
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0023.658-3.656
TTM0.0023.874-3.872
YOY0.0214.672-4.651
5Y0.0125.960-5.948
10Y0.0236.277-6.254
4.4.3.2. Quick Ratio

Measures if Respirerx is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Respirerx to the Biotechnology industry mean.
  • A Quick Ratio of 0.00 means the company can pay off $0.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of RespireRx Pharmaceuticals Inc:

  • The MRQ is 0.000. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.000. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.000TTM0.0000.000
TTM0.000YOY0.0000.000
TTM0.0005Y0.002-0.002
5Y0.00210Y0.012-0.011
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0003.104-3.104
TTM0.0003.426-3.426
YOY0.0004.498-4.498
5Y0.0025.933-5.931
10Y0.0126.426-6.414
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of RespireRx Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Respirerx assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Respirerx to Biotechnology industry mean.
  • A Debt to Asset Ratio of 522.50 means that Respirerx assets are financed with 52,250.1% credit (debt) and the remaining percentage (100% - 52,250.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of RespireRx Pharmaceuticals Inc:

  • The MRQ is 522.501. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 522.501. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ522.501TTM522.5010.000
TTM522.501YOY48.944+473.557
TTM522.5015Y175.924+346.577
5Y175.92410Y104.569+71.355
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ522.5010.354+522.147
TTM522.5010.345+522.156
YOY48.9440.311+48.633
5Y175.9240.366+175.558
10Y104.5690.382+104.187
4.5.4.2. Debt to Equity Ratio

Measures if Respirerx is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Respirerx to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of RespireRx Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.398-0.398
TTM-0.437-0.437
YOY-0.378-0.378
5Y-0.452-0.452
10Y-0.495-0.495
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Respirerx generates.

  • Above 15 is considered overpriced but always compare Respirerx to the Biotechnology industry mean.
  • A PE ratio of -0.27 means the investor is paying $-0.27 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of RespireRx Pharmaceuticals Inc:

  • The EOD is -0.083. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.273. Based on the earnings, the company is expensive. -2
  • The TTM is -0.273. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.083MRQ-0.273+0.190
MRQ-0.273TTM-0.2730.000
TTM-0.273YOY-1.567+1.294
TTM-0.2735Y-28.538+28.265
5Y-28.53810Y-42.448+13.910
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.083-2.160+2.077
MRQ-0.273-2.428+2.155
TTM-0.273-3.145+2.872
YOY-1.567-3.304+1.737
5Y-28.538-6.080-22.458
10Y-42.448-6.625-35.823
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of RespireRx Pharmaceuticals Inc:

  • The EOD is -2.295. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -7.540. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -7.540. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.295MRQ-7.540+5.245
MRQ-7.540TTM-7.5400.000
TTM-7.540YOY-5.772-1.768
TTM-7.5405Y-166.037+158.497
5Y-166.03710Y-267.533+101.495
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.295-2.980+0.685
MRQ-7.540-3.295-4.245
TTM-7.540-3.682-3.858
YOY-5.772-4.523-1.249
5Y-166.037-8.162-157.875
10Y-267.533-9.239-258.294
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Respirerx is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.09 means the investor is paying $-0.09 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of RespireRx Pharmaceuticals Inc:

  • The EOD is -0.028. Based on the equity, the company is expensive. -2
  • The MRQ is -0.091. Based on the equity, the company is expensive. -2
  • The TTM is -0.091. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.028MRQ-0.091+0.064
MRQ-0.091TTM-0.0910.000
TTM-0.091YOY-0.552+0.460
TTM-0.0915Y-12.126+12.035
5Y-12.12610Y-43.767+31.641
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.0281.869-1.897
MRQ-0.0912.027-2.118
TTM-0.0912.365-2.456
YOY-0.5522.419-2.971
5Y-12.1263.668-15.794
10Y-43.7674.362-48.129
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2018-12-312019-12-312020-12-312021-12-312022-12-31
Income Tax Expense  279126405141546179725-805-80



6.2. Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets23
Total Liabilities11,903
Total Stockholder Equity-11,880
 As reported
Total Liabilities 11,903
Total Stockholder Equity+ -11,880
Total Assets = 23

Assets

Total Assets23
Total Current Assets23
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 0
Total Current Assets  (as reported)23
Total Current Assets  (calculated)0
+/- 23
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities11,729
Long-term Liabilities174
Total Stockholder Equity-11,880
Total Current Liabilities
Short-term Debt 2,709
Short Long Term Debt 2,709
Accounts payable 5,724
Other Current Liabilities 9,020
Total Current Liabilities  (as reported)11,729
Total Current Liabilities  (calculated)20,162
+/- 8,433
Long-term Liabilities
Other Liabilities 174
Long-term Liabilities  (as reported)174
Long-term Liabilities  (calculated)174
+/-0
Total Stockholder Equity
Common Stock126
Retained Earnings -176,058
Other Stockholders Equity 164,030
Total Stockholder Equity (as reported)-11,880
Total Stockholder Equity (calculated)-11,902
+/- 22
Other
Capital Stock147
Cash and Short Term Investments 0
Common Stock Shares Outstanding 111,323
Current Deferred Revenue-5,724
Liabilities and Stockholders Equity 23
Net Debt 2,709
Net Invested Capital -9,193
Net Tangible Assets -11,902
Net Working Capital -11,706
Short Long Term Debt Total 2,709



6.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-311999-12-311998-12-311997-12-311996-12-311995-12-311994-12-311993-12-311992-12-311991-12-311990-12-311989-12-311988-12-311987-12-31
> Total Assets 
0
1,400
3,900
3,300
3,100
1,900
10,400
4,900
4,900
5,014
2,875
1,549
3,488
5,540
5,540
2,981
2,179
29,912
17,989
10,435
18,429
5,152
706
3,567
1,821
199
52
199
146
234
195
124
45
85
209
23
232098545124195234146199521991,8213,5677065,15218,42910,43517,98929,9122,1792,9815,5405,5403,4881,5492,8755,0144,9004,90010,4001,9003,1003,3003,9001,4000
   > Total Current Assets 
0
200
2,900
2,400
2,100
1,200
9,700
3,900
3,900
4,180
2,196
970
3,056
5,010
5,010
2,496
1,847
28,356
17,516
9,974
17,531
4,296
246
3,276
1,745
0
52
169
86
196
177
121
45
85
209
23
232098545121177196861695201,7453,2762464,29617,5319,97417,51628,3561,8472,4965,0105,0103,0569702,1964,1803,9003,9009,7001,2002,1002,4002,9002000
       Cash And Cash Equivalents 
0
200
2,700
2,300
2,000
1,200
200
100
100
4,092
2,124
909
2,705
4,558
4,558
1,849
1,125
9,157
2,063
1,649
4,021
1,431
226
1,038
1,611
152
14
152
53
92
85
33
17
1
1
0
0111733859253152141521,6111,0382261,4314,0211,6492,0639,1571,1251,8494,5584,5582,7059092,1244,0921001002001,2002,0002,3002,7002000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
247
192
181
83
12,211
18,839
15,198
7,799
13,264
2,710
0
1,993
48
0
0
0
0
0
0
0
0
0
0
0
00000000000481,99302,71013,2647,79915,19818,83912,21183181192247000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
115
428
42
15
160
0
0
0
0
0
0
0
48
0
0
0
0
0
0
0
0
000000004800000001601542428115000000000000000
       Other Current Assets 
0
0
200
100
100
0
9,500
3,800
3,800
88
72
61
351
261
453
351
211
31
241
365
247
155
20
90
86
17
38
17
29
55
92
88
28,638,000
84,262,000
207,339,000
22,693,000
22,693,000207,339,00084,262,00028,638,00088925529173817869020155247365241312113514532613516172883,8003,8009,500010010020000
   > Long-term Assets 
0
1,200
1,000
900
1,000
700
700
1,000
1,000
834
679
579
432
530
530
485
332
1,557
472
461
897
856
460
291
76
0
0
30
60
38
18
3
0
53
178
0
017853031838603000762914608568974614721,5573324855305304325796798341,0001,0007007001,0009001,0001,2000
       Property Plant Equipment 
0
400
700
700
800
700
700
900
900
808
655
532
399
497
497
451
298
388
439
428
851
809
383
250
67
0
0
17
12
5
0
0
0
0
0
0
0000005121700672503838098514284393882984514974973995326558089009007007008007007004000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
33
33
34
33
34
0
34
33
47
47
77
41
9
30
0
62
48
33
18
3
0
-53
-178
0
0-178-530318334862030941774747333403433343333000000000000
> Total Liabilities 
0
1,800
1,400
3,200
800
300
700
1,600
1,600
1,369
3,906
1,712
1,135
5,420
5,420
3,573
3,599
6,266
2,857
2,114
1,752
1,756
2,234
1,164
1,145
3,191
4,240
3,190
3,008
5,727
4,550
5,857
7,490
8,148
10,216
11,903
11,90310,2168,1487,4905,8574,5505,7273,0083,1904,2403,1911,1451,1642,2341,7561,7522,1142,8576,2663,5993,5735,4205,4201,1351,7123,9061,3691,6001,6007003008003,2001,4001,8000
   > Total Current Liabilities 
0
600
200
300
800
300
700
600
600
330
497
1,712
1,135
3,027
3,027
2,846
3,352
2,285
2,807
2,056
1,727
1,756
2,222
1,156
1,145
3,191
4,240
3,190
3,008
5,727
4,550
5,857
7,490
8,148
9,922
11,729
11,7299,9228,1487,4905,8574,5505,7273,0083,1904,2403,1911,1451,1562,2221,7561,7272,0562,8072,2853,3522,8463,0273,0271,1351,7124973306006007003008003002006000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
9
0
999
999
147
0
2,186,924
988,213
264
543
0
0
0
0
275
300
0
930
465
863
1,103
1,149
1,250
1,634
1,684
2,078
2,709
2,7092,0781,6841,6341,2501,1491,10386346593003002750000543264988,2132,186,924014799999909000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
930
577
863
1,103
1,149
1,250
1,634
1,684
2,078
2,709
2,7092,0781,6841,6341,2501,1491,10386357793000000000000000000000000000
       Accounts payable 
0
0
0
0
100
100
500
400
400
217
408
523
470
392
392
226
852
1,366
1,852
1,413
971
1,123
1,575
394
473
1,510
1,830
2
1,349
2
2,922
3
3,772
4,924
5,236
5,724
5,7245,2364,9243,77232,92221,34921,8301,5104733941,5751,1239711,4131,8521,3668522263923924705234082174004005001001000000
       Other Current Liabilities 
0
600
200
300
700
200
200
200
200
104
89
99
665
258
405
2,452
2,287
278
286
643
756
633
647
475
324
885
1,480
2,724
795
4,622
479
4,608
5,856
6,465
7,844
9,020
9,0207,8446,4655,8564,6084794,6227952,7241,4808853244756476337566432862782,2872,45240525866599891042002002002007003002006000
   > Long-term Liabilities 
0
1,200
1,200
2,900
100
100
500
1,010
1,000
1,039
3,409
1,523
470
2,394
2,394
727
247
3,981
50
58
25
1,123
11
8
521
0
0
465
863
1,103
4,071
1,250
1,634
1,684
294
174
1742941,6841,6341,2504,0711,103863465005218111,1232558503,9812477272,3942,3944701,5233,4091,0391,0001,0105001001002,9001,2001,2000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
2,393
727
247
381
0
50
59
25
0
11
8
0
0
0
0
0
0
0
0
0
0
294
174
1742940000000000811025595003812477272,3930000000000000
> Total Stockholder Equity
0
-400
2,500
100
2,300
1,600
9,700
3,300
3,300
3,645
-1,031
-163
2,353
120
120
-592
-1,420
23,647
15,132
8,320
16,677
3,397
-1,528
2,403
676
0
-4,210
-2,992
-2,862
-5,493
-4,355
-5,733
-7,445
-8,063
-10,008
-11,880
-11,880-10,008-8,063-7,445-5,733-4,355-5,493-2,862-2,992-4,21006762,403-1,5283,39716,6778,32015,13223,647-1,420-5921201202,353-163-1,0313,6453,3003,3009,7001,6002,3001002,500-4000
   Common Stock
0
0
0
0
0
0
0
0
7
7
10
16
17
17
17
17
17
33
33
35
48
48
68
79
86
144
144
144
490
2
3
4
4
71
98
126
126987144324901441441448679684848353333171717171716107700000000
   Retained Earnings Total Equity000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
-100
-200
-300
-500
-600
-900
-900
0
0
0
-92
-2,004
-2,004
-2,157
0
-243
-188
-3
27
-4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000-427-3-188-2430-2,157-2,004-2,004-92000-900-900-600-500-300-200-10000
   Capital Surplus 000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000
   Other Stockholders Equity 
0
1,300
6,500
6,800
11,500
11,800
24,700
25,400
25,400
28,047
36,276
38,811
41,638
44,002
44,039
44,441
42,630
77,965
81,000
90,057
111,340
112,686
118,525
120,816
121,338
0
0
125,184
144,648
151,994
157,422
158,635
159,038
162,654
163,828
164,030
164,030163,828162,654159,038158,635157,422151,994144,648125,18400121,338120,816118,525112,686111,34090,05781,00077,96542,63044,44144,03944,00241,63838,81136,27628,04725,40025,40024,70011,80011,5006,8006,5001,3000



6.4. Balance Sheets

Currency in USD. All numbers in thousands.




6.5. Cash Flows

Currency in USD. All numbers in thousands.




6.6. Income Statements

Currency in USD. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2022-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-1,579
Operating Income-1,579-1,579
 
Operating Expense (+$)
Research Development430
Selling General Administrative1,150
Selling And Marketing Expenses0
Operating Expense1,5791,579
 
Net Interest Income (+$)
Interest Income0
Interest Expense-604
Other Finance Cost-0
Net Interest Income-604
 
Pretax Income (+$)
Operating Income-1,579
Net Interest Income-604
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-2,103-1,056
EBIT - interestExpense = -3,834
-2,103
-1,418
Interest Expense604
Earnings Before Interest and Taxes (EBIT)-3,230-1,499
Earnings Before Interest and Taxes (EBITDA)-1,651
 
After tax Income (+$)
Income Before Tax-2,103
Tax Provision-0
Net Income From Continuing Ops-2,103-2,103
Net Income-2,022
Net Income Applicable To Common Shares-3,973
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses1,579
Total Other Income/Expenses Net-523604
 

Technical Analysis of Respirerx
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Respirerx. The general trend of Respirerx is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Respirerx's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of RespireRx Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.0008 < 0.0008 < 0.0008.

The bearish price targets are: 0.0004 > 0.0004 > 0.0004.

Tweet this
RespireRx Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of RespireRx Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

RespireRx Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of RespireRx Pharmaceuticals Inc. The current macd is -0.00016359.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Respirerx price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Respirerx. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Respirerx price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
RespireRx Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartRespireRx Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of RespireRx Pharmaceuticals Inc. The current adx is 13.64.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Respirerx shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
RespireRx Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of RespireRx Pharmaceuticals Inc. The current sar is 0.00180198.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
RespireRx Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of RespireRx Pharmaceuticals Inc. The current rsi is 43.54. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
RespireRx Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartRespireRx Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of RespireRx Pharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Respirerx price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
RespireRx Pharmaceuticals Inc Daily Stochastic Oscillator ChartRespireRx Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of RespireRx Pharmaceuticals Inc. The current cci is -54.53618756.

RespireRx Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartRespireRx Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of RespireRx Pharmaceuticals Inc. The current cmo is -21.03716537.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
RespireRx Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartRespireRx Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of RespireRx Pharmaceuticals Inc. The current willr is -88.88888889.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
RespireRx Pharmaceuticals Inc Daily Williams %R ChartRespireRx Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of RespireRx Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of RespireRx Pharmaceuticals Inc. The current atr is 0.00023393.

RespireRx Pharmaceuticals Inc Daily Average True Range (ATR) ChartRespireRx Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of RespireRx Pharmaceuticals Inc. The current obv is -595,238,512.

RespireRx Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartRespireRx Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of RespireRx Pharmaceuticals Inc. The current mfi is 82.04.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
RespireRx Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartRespireRx Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for RespireRx Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-07-15MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-07-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-07-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-05MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-09-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-18STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-23STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-09STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-10-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-24ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-06STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-15MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-25STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

RespireRx Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of RespireRx Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.536
Ma 20Greater thanMa 500.001
Ma 50Greater thanMa 1000.001
Ma 100Greater thanMa 2000.001
OpenGreater thanClose0.001
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Respirerx with someone you think should read this too:
  • Are you bullish or bearish on Respirerx? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Respirerx? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about RespireRx Pharmaceuticals Inc

I send you an email if I find something interesting about RespireRx Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about RespireRx Pharmaceuticals Inc.

Receive notifications about RespireRx Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.